Details for Patent: 8,790,700

Which drugs does patent 8,790,700 protect, and when does it expire?

Patent 8,790,700 protects TUZISTRA XR and is included in one NDA.

This patent has twenty-one patent family members in fourteen countries.

Summary for Patent: 8,790,700

Patent landscape, scope, and claims:

Title:	Modified release formulations containing drug-ion exchange resin complexes
Abstract:	An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described.
Inventor(s):	Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ)
Assignee:	TRIS Pharma, Inc. (Monmouth Junction, NJ)
Application Number:	14/044,105
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 8,790,700

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tris Pharma Inc	TUZISTRA XR	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	207768-001	Apr 30, 2015		DISCN	Yes	No			Y

International Family Members for US Patent 8,790,700

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E536867
Australia	2007227569
Brazil	PI0709606
Canada	2645855